Variant Pharmaceuticals, Inc.

May 01, 2019

Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.

Apr 22, 2019

Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor

Dec 03, 2018

Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.

Oct 24, 2018

Variant Pharmaceuticals Announces Publication of Data Demonstrating 2-Hydroxypropyl-b-Cyclodextrin (2HPbCD) Protects Against Kidney Disease in Experimental Models of Alport Syndrome (AS) and Focal Segmental Glomerulosclerosis (FSGS)

Oct 16, 2018

Variant Pharmaceuticals Receives Notice of Allowance in Two U.S. Patent Applications Covering Lead Compound, 2-hydroxypropyl-b-cyclodextrin, a Phase 2a-ready Asset for Rare Renal Disease, Focal Segmental Glomerulosclerosis (FSGS)

Oct 09, 2018

Variant Pharmaceuticals Enhances Its Board of Directors with Three New Members

Apr 16, 2018

Variant Pharmaceuticals Completes Pre-IND Meeting with FDA on VAR 200 for Focal Segmental Glomerulosclerosis (FSGS), a Rare Kidney Disease